Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T790M Positive NSCLC Patients”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT03861156
What this trial is testing

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Who this might be right for
Solid TumorNSCLCEGFR T790M
InventisBio Co., Ltd 290
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Large-scale testing (Phase 3)Study completedNCT02997501
What this trial is testing

T790M Plasma Testing Methodology Comparison and Clinical Validation

Who this might be right for
Lung Cancer
AstraZeneca 256
Testing effectiveness (Phase 2)Ended earlyNCT02485652
What this trial is testing

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 162
Large-scale testing (Phase 3)Study completedNCT02474355
What this trial is testing

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 3,017
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)UnknownNCT02330367
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 368
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT03386955
What this trial is testing

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Beta Pharma Shanghai 215
Not applicableStudy completedNCT03457220
What this trial is testing

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 423
Testing effectiveness (Phase 2)UnknownNCT03300115
What this trial is testing

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 222
Early research (Phase 1)Study completedNCT02914990
What this trial is testing

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Not applicableNo Longer AvailableNCT02451852
What this trial is testing

AZD9291 US Expanded Access Program

Who this might be right for
EGFR T790M Mutation Positive NSCLC
AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Load More Results